secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001213900-24-029811
Event type: regulatory
Sentiment:  negative
Materiality: 0.82
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax receives Nasdaq deficiency notice; equity of $1.93M below $2.5M minimum
------------------------------------------------------------------------------

- Nasdaq notified Virpax of non-compliance with Listing Rule 5550(b)(1); stockholders' equity was $1,934,321 as of Dec 31, 2023.
- Company also fails alternative standards of $35M market value or $500K net income in last fiscal year.
- Has 45 calendar days (by May 17, 2024) to submit a plan to regain compliance; extension of up to 180 days possible if plan accepted.
- Non-compliance has no immediate effect on listing; hearing rights exist if plan rejected or fails.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024029811/0001213900-24-029811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024029811/ea0203247-8k_virpax.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-029811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer